Allergan board unanimously rebuffs latest acquisition offer from Valeant, Pershing Square
Allergan's board is unanimously rejecting the latest takeover bid from Valeant Pharmaceuticals, and the Botox maker says the offer isn't even worth talking about.
Allergan says a May 30 offer from the Canadian drugmaker and activist investor Bill Ackman's Pershing Square Capital Management still substantially undervalues Allergan Inc. and creates too much risk for shareholders. Allergan also says the deal doesn't offer enough value to warrant discussions between the companies.
That deal amounts to around $53 billion. It includes $72 in cash and a portion of Valeant Pharmaceuticals International Inc. stock for each Allergan share and was up from a previous bid that involved $58.30 in cash and the stock portion.
Ackman is a big Allergan shareholder. He has said he will move to replace most of Allergan's board.
Read more Business News
- Tour operator condemnedBC - 8:47 am
- Firefighters fill boots w cashCentral Okanagan - 8:26 am
- Consultation for cell towers?Poll
- Tranquille Road celebrationKamloops - 9:56 am
|QHR Technologies Inc||1.37||+0.05|
|Anavex Life Sciences||0.223||-0.0031|
|Copper Mountain Mining||2.66||-0.02|
|Sunrise Resources Ltd||0.02||-0.005|
|Mission Ready Services||0.29||-0.01|
“Is this a fair offer from ICBC?”…. “How much should I settle for?”… “What is my claim worth?” These are just some of the questions I regularly get as...
Last night I was privileged to be able to speak at the Greater Westside Board of Trade business awards dinner. Photo: ContributedI talked about Innovation and Collaboration which are two very interes...
There will be a time when you will need to decide who you should appoint as executor of your Will. As well, there may be a time when you will be asked by someone to act as the executor of his or her W...